Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/128570
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
Author: Poprzeczny, A.J.
Louise, J.
Deussen, A.R.
Dodd, J.M.
Citation: BMC Endocrine Disorders, 2020; 20(1):139-1-139-9
Publisher: Springer Nature; BioMed Central
Issue Date: 2020
ISSN: 1472-6823
1472-6823
Statement of
Responsibility: 
Amanda J. Poprzeczny, Jennie Louise, Andrea R. Deussen and Jodie M. Dodd
Abstract: Background: The infants born to women who are overweight or obese in pregnancy are at an increased risk of being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown to be ineffective at reducing this risk. Our aim was to examine the effects of metformin in addition to a diet and lifestyle intervention on fetal growth and adiposity among women with a BMI above the healthy range. Methods: Women who had a body mass index ≥25 kg/m² in early pregnancy, and a singleton gestation, were enrolled in the GRoW trial from three public maternity hospitals in metropolitan Adelaide. Women were invited to have a research ultrasounds at 28 and 36 weeks' gestation at which ultrasound measures of fetal biometry and adiposity were obtained. Fetal biometry z-scores and trajectories were calculated. Measurements and calculations were compared between treatment groups. This secondary analysis was pre-specified. Results: Ultrasound data from 511 women were included in this analysis. The difference in femur length at 36 weeks' gestation was (0.07 cm, 95% CI 0.01-0.14 cm, p = 0.019) and this was was statistically significant, however the magnitude of effect was small. Differences between treatment groups for all other fetal biometry measures, z-scores, estimated fetal weight, and adiposity measures at 28 and 36 weeks' gestation were similar. Conclusions: The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity.
Keywords: Fetal growth; fetal adiposity; maternal obesity; metformin; antenatal interventions
Rights: © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
DOI: 10.1186/s12902-020-00618-0
Grant ID: http://purl.org/au-research/grants/nhmrc/1043181
http://purl.org/au-research/grants/nhmrc/1078980
Published version: http://dx.doi.org/10.1186/s12902-020-00618-0
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_128570.pdfPublished Version802.68 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.